Marimastat

Marimastat
Systematic (IUPAC) name

N-[2,2-dimethyl-1- (methylcarbamoyl)propyl]-2- [hydroxy-(hydroxycarbamoyl)methyl]- 4- methyl-pentanamide
Clinical data
Pregnancy category	N/A
Legal status	Development terminated?
Routes of administration	Oral
Identifiers
CAS Registry Number	154039-60-8^Y
ATC code	None
PubChem	CID 119031
DrugBank	DB00786^N
ChemSpider	106358^N
UNII	D5EQV23TDS^N
ChEMBL	CHEMBL279785^N
Chemical data
Formula	C₁₅H₂₉N₃O₅
Molecular mass	331.408 g/mol
SMILES O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
InChI InChI=1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1 ^N Key:OCSMOTCMPXTDND-OUAUKWLOSA-N ^N
N (what is this?) (verify)

Marimastat was a proposed antineoplastic drug developed by British Biotech. It acted as a broad-spectrum matrix metalloproteinase inhibitor.^[1]^[2]

Marimastat performed poorly in clinical trials,^[3] and development was terminated.

References

↑ "Marimastat". National Cancer Institute.
↑ Millar, AW; Brown PD; Moore J et al. (1998). "Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers". Br J Clin Pharmacol 45 (1): 21–6. PMC 1873993. PMID 9489589.
↑ Sparano, JA (2004). "Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196". J Clin Oncol 22 (23): 4683–90. doi:10.1200/JCO.2004.08.054. PMID 15570070.